TD Cowen lowered the firm’s price target on Cue Health to $1.50 from $5.00 and keeps an Outperform rating on the shares. The firm said the company expects approvals for its new respiratory tests may come as early as upcoming respiratory season. Cowen sees test approvals as next major catalyst for company.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HLTH:
